Expression of ASPH protein in retroperitoneal liposarcoma and its clinical significances
10.3760/cma.j.issn.1007-631X.2019.08.015
- VernacularTitle:腹膜后脂肪肉瘤中天冬氨酸-天冬酰胺β羟化酶蛋白的表达及其临床意义
- Author:
Mengmeng XIAO
1
;
Shibo LIU
;
Yuqing CUI
;
Lihua WANG
;
Jun CHEN
;
Chengli MIAO
;
Xiaosong RAO
;
Xuesong CHEN
;
Xiaoqun DONG
;
Jack WANDS
;
Chenghua LUO
Author Information
1. 北京大学国际医院腹膜后肿瘤外科 102206
- Keywords:
Liposarcoma;
Retroperitoneal tumors;
Survival rate;
Immunotherapy
- From:
Chinese Journal of General Surgery
2019;34(8):700-703
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of Aspartate Beta-Hydroxylase (ASPH) in retroperitoneal liposarcoma (RL)and evaluate its clinical significances.Methods Relevant clinical data of 69 RL cases after surgical resection were collected.The expression of ASPH in tumor tissues was detected by immunohistochemistry.The CTL epitopes of ASPH protein HLA-A2 were predicted by SYFPEITHI and NetMHCpan software.Results The overall positive rate of ASPH expression for the whole group was 81％,that for well-differentiated liposarcoma was 73％,dedifferentiated liposarcoma was 87％ (P ＜ 0.05).ASPH expression was positively correlated with the postoperative recurrence free survival rate (P ＜ 0.05).Five HLA-A2 restricted CTL epitopes (9 peptides) were screened with the method of motif prediction.Conclusions ASPH expression is positively correlated with the degree of malignancy of RL,and the ASPH expression is an independent risk factor for postoperative recurrence free survival rate of RL.Moreover,ASPH was found to have 5 HLA-A2 restricted CTL epitopes,which are expected to be used for the immunotherapy of RL.
